Dyax and Sigma-Tau Group Expand Agreement for KALBITOR® (ecallantide) in Hereditary Angioedema Additional Territories Include Countries in Latin America and Southeast Asia Expanded Agreement Includes $7M in Upfront Payment, Up to $10M in MilestonesExpansion Agreement • June 1st, 2011 • Dyax Corp • Services-commercial physical & biological research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2011--Dyax Corp. (NASDAQ: DYAX) and Defiante Farmaceutica S.A., an affiliate of the pharmaceutical group Sigma-Tau (Sigma-Tau), announced today an expansion of their strategic partnership for KALBITOR® (ecallantide) in the treatment of hereditary angioedema (HAE) and other therapeutic indications to include development and commercialization rights in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea. Under their existing agreement, Defiante holds these rights in Europe, North Africa, the Middle East, Russia, Australia and New Zealand, with Dyax retaining rights to KALBITOR in other territories, including the U.S., where it is approved for the treatment of acute attacks of HAE in patients 16 years of age and older.
